Literatur
-
1
Nedelmann C.
Das Verbot von Cannabis ist ein kollektiver Irrweg.
Deutsches Ärzteblatt.
2000;
97
A 2833-2835
-
2 Gold M S. Marijuana. In: Miller NS Comprehensive Handbook of Alcohol and Drug Addiction. New York; Marcel Decker 1991: 353-376
-
3
Ashton C H.
Pharmacology and effects of cannabis: a brief review.
Brit J Psychiat.
2001;
178
101-106
-
4 British Medical Association .Therapeutic uses of cannabis. London; Harwood Academic 1997
-
5
Thomas H.
Psychiatric symptoms in cannabis users.
Brit J Psychiat.
1993;
163
141-149
-
6
Thomas H.
A community survey of adverse effects of cannabis use.
Drug Alc Depend.
1996;
42
201-207
-
7
Troisi A, Pasini A, Saracco M. et al .
Psychiatric symptoms in male cannabis users not using other illicit drugs.
Addiction.
1998;
93
487-492
-
8
Reilly D, Didcott R, Swift W. et al .
Long-term cannabis use: characteristics of users in Australian rural areas.
Addiction.
1998;
93
837-846
-
9
Negrete J C, Knapp W P, Douglas D E, Smith W B.
Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey.
Psychol Medicine.
1986;
16
515-520
-
10
Tennant F S, Groesbeck C J.
Psychiatric effects of hashish.
Arch Gen Psychiat.
1972;
33
383-386
-
11 Hall W, Solowij N, Lemon J. The Health and Social Consequences of Cannabis Use. Monograph Series No. 25. Canberra; Australian Government Publishing Service 1994
-
12
Hambrecht M, Häfner H.
Cannabis, vulnerability, and the onset of schizophrenia - an epidemiological perspective.
Austral New Zealand J Psychiat.
2000;
34
468-475
-
13
Dixon L, Haas G, Weiden P J, Sweeney J, Frances A J.
Drug abuse in schizophrenic patients: Clinical correlates and reasons for use.
Am J Psychiatry.
1991;
148
224-230
-
14
Linszen D H, Dingemans P M, Lenior M E.
Cannabis abuse and the course of recent onset schizophrenic disorders.
Arch Gen Psychiat.
1994;
51
273-279
-
15
Leirer V O, Yesavage J A, Morrow D G.
Marijuana carry-over effects on aircraft pilot performance.
Aviation & Space Environmental Medicine.
1991;
62
221-227
-
16
Jones A.
Psychiatric effects of cannabis.
Brit J Psychiat.
2001;
178
116-122
-
17 World Health Organization .Programme on Substance Abuse. Cannabis: A Health Perspective and Research Agenda. Geneva; WHO 1997
-
18
Morgenstern J, Langenbucher J, Labouvie E W.
The generalizability of the dependence syndrome across substances: an examination of some properties of the proposed DSM-IV dependence criteria.
Addiction.
1994;
89
1105-1113
-
19
Wiesbeck G A, Schuckit M A, Kalmijn J A. et al .
An evaluation of the history of a marijuana withdrawal syndrome in a large population.
Addiction.
1996;
91
1469-1478
-
20
Manzanares J, Corchero J, Romero J J. et al .
Pharmacological and biochemical interactions between opiates and cannabinoids.
Trends in Pharmacological Sciences.
1999;
20
287-294
-
21
Tanda G, Pontieri F E, Di Chiara G.
Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.
Science.
1997;
276 (5321)
2048-2050
-
22
Rommelspacher H.
Cannabis. Als Arzneimittel nur von geringem therapeutischen Nutzen.
Deutsches Ärzteblatt.
2000;
97
B 2918-2920
Prof. Dr. med. Dr. phil. Martin Hambrecht
Klinik für Psychiatrie und Psychotherapie · Evang. Krankenhaus Elisabethenstift gGmbH
Landgraf-Georg-Straße 100
64287 Darmstadt
Email: hambrecht.martin@krankenhaus-elisabethenstift.de
